Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice

Cardiovascular Research

Volumn 65, Issue 4, 2005, Pages 879-888

  Liao, Yulin ^a   Asakura, Masanori ^a   Takashima, Seiji ^a   Ogai, Akiko ^b   Asano, Yoshihiro ^a   Asanuma, Hiroshi ^a   Minamino, Tetsuo ^a   Tomoike, Hitonobu ^b   Hori, Masatsugu ^a   Kitakaze, Masafumi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Calcium channel blocker; Gene expression; Heart failure; Hypertrophy

Indexed keywords

BENIDIPINE; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; ISOPROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; PROCOLLAGEN; PROTEIN; PROTEIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME LOCALIZATION; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOLOGY; MALE; MOUSE; NERVE CELL; NEWBORN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN SYNTHESIS; RAT;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CARDIOMEGALY; CELLS, CULTURED; COLLAGEN TYPE IV; DIHYDROPYRIDINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; MALE; MICE; MICE, INBRED C57BL; MUSCLE PROTEINS; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 13844272060     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.11.006     Document Type: Article

References (34)

1. B.M. Psaty, S.R. Heckbert, T.D. Koepsell, D.S. Siscovick, T.E. Raghunathan, and N.S. Weiss The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 274 1995 620 625
2. C.D. Furberg, B.M. Psaty, and J.V. Meyer Nifedipine: Dose-related increase in mortality in patients with coronary heart disease Circulation 92 1995 1326 1331
3. J. Muntwyler, and F. Follath Calcium channel blockers in treatment of hypertension Prog. Cardiovasc. Dis. 44 2001 207 216
4. S. Sanada, K. Node, T. Minamino, S. Takashima, A. Ogai, and H. Asanuma Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats Hypertension 41 2003 963 967
5. M. Kitakaze, K. Node, T. Minamino, H. Asanuma, T. Kuzuya, and M. Hori A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs J. Am. Coll. Cardiol. 33 1999 242 249
6. H. Asanuma, M. Kitakaze, K. Node, S. Takashima, Y. Sakata, and M. Asakura Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts Cardiovasc. Drugs Ther. 15 2001 225 231
7. A. Calderone, C.M. Thaik, N. Takahashi, D.L. Chang, and W.S. Colucci Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts J. Clin. Invest. 101 1998 812 818
8. M. Scherrer-Crosbie, R. Ullrich, K.D. Bloch, H. Nakajima, B. Nasseri, and H.T. Aretz Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice Circulation 104 2001 1286 1291
9. S. Jesmin, I. Sakuma, Y. Hattori, S. Fujii, and A. Kitabatake Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a type II diabetic rat model Diabetologia 45 2002 402 415
10. Y. Liao, F. Ishikura, S. Beppu, M. Asakura, S. Takashima, and H. Asanuma Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation Am. J. Physiol., Heart Circ. Physiol. 282 2002 H1703 H1708
11. Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, and Y. Shintani Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model Circ. Res. 93 2003 759 766
12. M. Takemoto, K. Node, H. Nakagami, Y. Liao, M. Grimm, and Y. Takemoto Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J. Clin. Invest. 108 2001 1429 1437
13. M. Asakura, M. Kitakaze, S. Takashima, Y. Liao, F. Ishikura, and T. Yoshinaka Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy Nat. Med. 8 2002 35 40
14. Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, and Y. Shintani Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice Circulation 110 2004 692 699
15. S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, and H. Sugino Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis Hypertension 41 2003 99 107
16. Y. Asano, S. Takashima, M. Asakura, Y. Shintani, Y. Liao, and T. Minamino Lamr1 functional retroposon causes right ventricular dysplasia in mice Nat. Genet. 36 2004 123 130
17. T. Tatsumi, K. Akashi, N. Keira, S. Matoba, A. Mano, and J. Shiraishi Cytokine-induced nitric oxide inhibits mitochondrial energy production and induces myocardial dysfunction in endotoxin-treated rat hearts J. Mol. Cell. Cardiol. 37 2004 775 784
18. H. Matsuoka, M. Nakata, K. Kohno, Y. Koga, G. Nomura, and H. Toshima Chronic l-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats Hypertension 27 1996 14 18
19. B.S. Burlew, and K.T. Weber Connective tissue and the heart. Functional significance and regulatory mechanisms Cardiol. Clin. 18 2000 435 442
20. B. Hemmens, S. Woschitz, E. Pitters, B. Klosch, C. Volker, and K. Schmidt The protein inhibitor of neuronal nitric oxide synthase (PIN): characterization of its action on pure nitric oxide synthases FEBS Lett. 430 1998 397 400
21. S.P. Jones, J.J. Greer, R. van Haperen, D.J. Duncker, R. De Crom, and D.J. Lefer Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice Proc. Natl. Acad. Sci. U. S. A. 100 2003 4891 4896
22. M. Murakami, S. Kusachi, M. Nakahama, I. Naito, T. Murakami, and M. Doi Expression of the alpha 1 and alpha 2 chains of type IV collagen in the infarct zone of rat myocardial infarction J. Mol. Cell. Cardiol. 30 1998 1191 1202
23. D. Chapman, K.T. Weber, and M. Eghbali Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium Circ. Res. 67 1990 787 794
24. K. Doi, F. Sawada, G. Toda, S. Yamachika, S. Seto, and Y. Urata Alteration of antioxidants during the progression of heart disease in streptozotocin-induced diabetic rats Free Radic. Res. 34 2001 251 261
25. T. Watanabe, S. Kusachi, A. Yamanishi, H. Kumashiro, H. Nunoyama, and I. Sano Localization of type IV collagen alpha chain in the myocardium of dilated and hypertrophic cardiomyopathy Jpn. Heart J. 39 1998 753 762
26. D.C. Crawford, A.V. Chobanian, and P. Brecher Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat Circ. Res. 74 1994 727 739
27. T. Hamada, M. Watanabe, T. Kaneda, A. Ohtahara, T. Kinugawa, and I. Hisatome Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine J. Hypertens 16 1998 111 118
28. A. Zanchetti, M.G. Bond, M. Hennig, A. Neiss, G. Mancia, and C. Dal Palu Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial Circulation 106 2002 2422 2427
29. M. Packer, C.M. O'Connor, J.K. Ghali, M.L. Pressler, P.E. Carson, R.N. Belkin Prospective Randomized Amlodipine Survival Evaluation Study Group Effect of amlodipine on morbidity and mortality in severe chronic heart failure N. Engl. J. Med. 335 1996 1107 1114
30. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
31. Y.F. Li, and K.P. Patel Paraventricular nucleus of the hypothalamus and elevated sympathetic activity in heart failure: the altered inhibitory mechanisms Acta Physiol. Scand. 177 2003 17 26
32. L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahlof, J. Lanke, and B. Schersten Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 354 1999 1751 1756
33. Y. Asano, J. Kim, A. Ogai, S. Takashima, Y. Shintani, and T. Minamino A calcium channel blocker activates both ecto-5(′)-nucleotidase and NO synthase in HUVEC Biochem. Biophys. Res. Commun. 311 2003 625 628
34. H. Lenasi, K. Kohlstedt, B. Fichtlscherer, A. Mulsch, R. Busse, and I. Fleming Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495 Cardiovasc. Res. 59 2003 844 853